Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FluoroPharma Medical Inc FPMI

Healthcare Biotechnology
FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The Company is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular... see more

Recent & Breaking News (GREY:FPMI)

FPMI Restructures CardioPET License With Massachusetts General Hospital

GlobeNewswire September 27, 2018

FPMI Acquires Exclusive Option to License Ground Fluor’s Advanced Neuronal PET imaging Agent

Business Wire June 25, 2018

FluoroPharma Announces Closing of Stock Buyback Transaction

GlobeNewswire January 10, 2018

FluoroPharma Medical Announces Details for Investor Call on January 6th

Marketwired January 5, 2016

FluoroPharma Names Dr. Thomas Tulip, PhD Chief Executive Officer

Marketwired December 29, 2015

Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves

Marketwired October 23, 2015

Healthcare Industry Veteran, Thomas Tulip, Joins FluoroPharma Medical, Inc.

Marketwired October 6, 2015

FluoroPharma Medical to Present Business Updates at the Noble Financial Capital Markets' Eleventh Annual Equity Conference January 21, 2015

Marketwired January 16, 2015

FluoroPharma Medical Announces Scheduled Completion of Enrollment in a Phase II Clinical Trial of CardioPET (18F FCPHA) for Assessment of Coronary Artery Disease (CAD)

Marketwired December 4, 2014

Journal of Nuclear Cardiology Publication States Preliminary Findings of Phase II Clinical Study Suggest FluoroPharma's CardioPET Has a Promising Role for the Identification of Functionally Significant Coronary Artery Disease

Marketwired November 3, 2014

FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden

Marketwired October 20, 2014

FluoroPharma Medical Announces Acceptance of Abstract from Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral Presentation at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden

Marketwired October 6, 2014

FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the 19th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC), September 20th in Boston, MA

Marketwired September 22, 2014

FluoroPharma Medical Announces Acceptance of Abstract From Phase II Clinical Trial of CardioPET (18F FCPHA) for Oral Presentation at the 19th Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC), September 18-21, 2014, in Boston

Marketwired September 2, 2014

FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 10th in St. Louis, MO

Marketwired June 11, 2014

FluoroPharma Medical Announces Presentation of Data From Phase II Clinical Trial of 18F FCPHA (CardioPET) at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 7-14, in St. Louis, MO

Marketwired May 29, 2014

FluoroPharma Medical Chairman & CEO to Present at 15th Annual B. Riley Conference on May 19th at 4:00 pm PDT

Marketwired May 19, 2014

FluoroPharma Appoints Dr. H. William Strauss, Internationally Recognized Expert in the Field of Cardiovascular Nuclear Medicine, to Chair the Scientific Advisory Board

Marketwired April 14, 2014

FluoroPharma CEO Thijs Spoor to Be Interviewed Live Today on Clear Channel Business Talk Radio

Marketwired April 2, 2014

FluoroPharma CEO Thijs Spoor to Be Interviewed Live Today on Clear Channel Business Talk Radio

Marketwired April 2, 2014